VANCOUVER and GLIL YAM, Israel

温哥华和以色列格利尔亚姆

,

，

Nov. 4, 2026

2026年11月4日

/PRNewswire/ --

/美通社/ --

IM Cannabis Corp.

IM大麻公司

('

（'

IMCC

国际海事犯罪中心

' or the '

或

Company

公司

') (Nasdaq:

'）（纳斯达克：

IMCC

国际海事犯罪中心

), a medical cannabis company with operations in Israel, today announced the closing of a US$1,200,000 convertible note financing in a private placement with an existing institutional investor (the '

），一家在以色列开展业务的医用大麻公司，今日宣布完成一项与现有机构投资者进行的私募可转换票据融资，金额为120万美元（“

Investor

投资者

').

'）。

Pursuant to a note purchase agreement between the Company and Investor dated November 4, 2026 (the '

根据公司与投资者于2026年11月4日签订的票据购买协议（“

November

十一月

Note Purchase Agreement

票据购买协议

'), the Company issued the Investor a convertible promissory note in the principal amount of US$1,200,000, with an original issuance discount of 15% (the '

），本公司向投资者发行了本金金额为120万美元的可转换本票，原始发行折扣为15%（“

November

十一月

Note

注意

').

').

The November Note bears interest at a rate of 4% per annum, increasing to 14% upon the occurrence and continuation of an event of default, as defined in the November Note. The November Note provides the Investor the option of converting on one or more occasions all or part of the outstanding balance of the Company's obligations thereunder through the issuance of common shares in the capital of the Company (the '.

十一月票据按年利率4%计息，在发生并持续存在违约事件（定义见十一月票据）时，利率将上调至14%。十一月票据赋予投资者一项选择权，可一次或多次通过发行公司资本中的普通股，将其在公司项下未偿余额的全部或部分转换为股权（即“

Common Shares

普通股

').

').

The November Note matures 28 months from issuance and is repayable in 10 equal monthly instalments beginning after the 18

11月票据自发行之日起28个月后到期，需在第18个月之后分10期等额按月偿还。

th

泰国

month. Under the November Note Purchase Agreement, beginning January 1, 2027 the Company may, at its discretion, request that the Investor purchase additional convertible notes of up to US$1,200,000 in each three-month period, each with accompanying warrants, on substantially the same terms.

月。根据《十一月票据购买协议》，自2027年1月1日起，公司可自行决定要求投资者在每个三个月期间内购买额外可转换票据，金额最高为120万美元，每张票据均附有认股权证，条款基本相同。

The conversion price in the November Note is set to the lower of (i) a fixed price of US$0.610 per Common Share, or (ii) 85% of the lowest daily volume-weighted average price during the 20 consecutive trading days preceding the conversion date, subject to a floor price of US$0.1449 per Common Share.

11月票据的转换价格定为以下两者中的较低者：(i) 每股普通股0.610美元的固定价格，或 (ii) 转换日前连续20个交易日内每日成交量加权平均价格的最低值的85%，但须受每股普通股0.1449美元的底价限制。

The November Note includes customary limitations, including a 4.99% beneficial ownership cap..

11月票据包含惯常的限制条款，包括4.99%的受益所有权上限。

In connection with the November Note, the Company also issued the Investor a warrant to purchase up to 3,936,330 Common Shares (the '

就11月票据而言，本公司亦向投资者发行了认股权证，使其有权购买最多3,936,330股普通股（“

November

十一月

Note Warrants

附认股权证票据

') at an exercise price of US$0.610 per Common Share. The November Note Warrants became immediately exercisable upon their issuance date, November 4, 2026, and will expire after three years, on November 3, 2029. The November Note Warrants include certain anti-dilution and ratchet adjustment provisions..

）行权价为每股普通股0.610美元。十一月票据认股权证自其发行日2026年11月4日起即可立即行权，并将于三年后的2029年11月3日到期。十一月票据认股权证包含某些反稀释和棘轮调整条款。

The Company intends to use the net proceeds from the November Note for general corporate purposes.

公司拟将十一月票据的净收益用于一般企业用途。

In connection with the November Note Purchase Agreement, the Company has agreed to reserve sufficient Common Shares for issuance upon conversion of the November Note and exercise of the November Note Warrants and to file a resale registration statement on Form F-3 with the U.S. Securities and Exchange Commission (the '.

就十一月票据购买协议而言，公司已同意预留足够的普通股，以供在转换十一月票据及行使十一月票据权证时发行，并向美国证券交易委员会提交一份F-3表格的转售注册声明。

SEC

美国证券交易委员会

') and to use commercially reasonable efforts to secure its effectiveness within the timeframes agreed with the Investor.

）并尽商业上合理的努力，在与投资者约定的时间框架内确保其生效。

All securities issued under the financing described above are subject to: (i) a four month and one day hold period from the date of issuance under applicable Canadian securities laws and (ii) applicable legends as required pursuant to the U.S. Securities Act of 1933, as amended (the '

根据上述融资发行的所有证券均须遵守：(i) 根据适用的加拿大证券法，自发行之日起四个月的禁售期；以及 (ii) 根据经修订的《1933年美国证券法》所要求的适用声明。

Securities Act

证券法

'). The private placement of the securities offered to the Investor was made in reliance on an exemption from (x) registration under Section 4(a)(2) of the Securities Act and (y) applicable Canadian securities laws. Accordingly, the securities issued in the private placement may not be offered or sold in the United States or Canada except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws or an exemption pursuant to Canadian securities laws..

）。向投资者提供的证券私募发行是依据以下豁免进行的：(x) 《证券法》第4(a)(2)条规定的注册豁免，以及(y) 适用的加拿大证券法豁免。因此，除非根据有效的注册声明，或依据《证券法》及适用的州证券法的注册要求豁免，或依据加拿大证券法的豁免，否则不得在美国或加拿大要约出售或销售该等私募发行的证券。

About IM Cannabis Corp.

关于IM Cannabis Corp.

IM Cannabis Corp. (Nasdaq:

IM Cannabis Corp.（纳斯达克：

IMCC

国际货币基金组织条件性

) is an international company currently operating a medical cannabis platform serving patients in Israel.

）是一家国际公司，目前运营着一个为以色列患者服务的医用大麻平台。

The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms in Israel that enable the safe delivery and quality control of IMCC's products throughout the value chain..

该公司通过其子公司在以色列运营生态系统，利用多年积累的专有数据和患者洞察，向医疗患者进口和分销大麻。该公司还在以色列运营医疗大麻零售药店和在线平台，确保IMCC产品在整个价值链中的安全交付和质量控制。

Company Contact:

公司联系人：

Michal Efraty

米哈尔·埃夫拉蒂

Investor & Public Relations

投资者与公共关系

IM Cannabis Corp.

IM 大麻公司

michal@efraty.com

michal@efraty.com

Oren Shuster, Chief Executive Officer

奥伦·舒斯特，首席执行官

IM Cannabis Corp.

IM 大麻公司

info@imcannabis.com

info@imcannabis.com

Disclaimer for Forward-Looking Statements

前瞻性陈述免责声明

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, '

本新闻稿包含根据适用的加拿大和美国证券法（统称为“

forward-looking statements

前瞻性陈述

'). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'believe', 'plan', 'estimate', 'expect', 'likely' and 'intend' and statements that an event or result 'may', 'will', 'should', 'could' or 'might' occur or be achieved and other similar expressions.

）。所有涉及我们预期未来将发生的活动或发展的信息均为前瞻性陈述。前瞻性陈述通常（但并非总是）通过使用“寻求”、“预期”、“相信”、“计划”、“估计”、“期望”、“可能”和“打算”等词语，以及声称某事件或结果“可能”、“将会”、“应该”、“能够”或“或许”发生或实现的其他类似表述来识别。

Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the receipt of and use of proceeds from the financing and the preparation, timing and filing of the registration statement with the SEC.

前瞻性陈述基于管理层在作出该等陈述之日的估计和意见。在本新闻稿中，此类前瞻性陈述包括但不限于与以下事项相关的陈述：融资所得款项的收取及使用，以及向美国证券交易委员会（SEC）提交注册声明的准备工作、时间安排及提交事宜。

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks.

上述前瞻性陈述及假设清单并非详尽无遗。由于前瞻性陈述涉及未来事件和状况，其性质本身即包含固有的风险和不确定性。受多种因素和风险的影响，实际结果可能与当前预期或此类前瞻性陈述所暗示的结果存在重大差异。

These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the '.

这些包括：公司在高度监管的行业中未能遵守适用的监管要求；公司运营所在司法管辖区的政府政策和法规发生意外变化；公司持续满足纳斯达克资本市场上市要求的能力；任何未能保持良好信誉或更新其许可证的意外情况；公司及其子公司（统称“

Group

群组

') to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the multi front war Israel is facing on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel market; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company's inability to use the proceeds as set out herein; and the Company's inability to file a registration statement in the timelines outlined herein or at all..

’）以履行其销售承诺或实现增长目标；集团依赖第三方供应协议提供足够数量的医用大麻以履行集团义务；集团可能面临的法律责任、与此相关的感知风险水平，以及涉及集团的任何诉讼或其他类似争议或法律程序的预期结果；竞争加剧的影响；缺乏并购机会；不利的市场状况；产量、质量和成本估算固有的不确定性，以及产生意外成本和费用的可能性；因使用集团大麻产品而导致的产品责任及其他与安全相关的责任风险；供应链限制；对关键人员的依赖；现有债务违约的风险；东欧和中东地区战争、冲突和内乱相关的风险，包括以色列面临的多线战争对公司、其在以色列的运营以及以色列医用大麻行业的影响；与公司专注于以色列市场相关的风险；公司无法实现可持续盈利和/或提升股东价值；公司无法积极管理成本和/或提高利润率；公司无法增长和/或维持销售额；公司无法实现其目标和/或战略计划；公司无法降低成本和/或维持收入；公司无法按本文所述使用所得款项；以及公司无法在本文规定的时间范围内或根本无法提交注册声明。

Please see the other risks, uncertainties and factors set out under the heading 'Risk Factors' in the Company's annual report for the year ended December 31, 2025, which is available on the Company's issuer profile on SEDAR+ at

请参阅本公司截至2025年12月31日止年度的年度报告中“风险因素”标题下所列的其他风险、不确定性和因素，该报告可通过SEDAR+上的本公司发行人档案获取，网址为

www.sedarplus.ca

www.sedarplus.ca

and Edgar at

以及埃德加在

www.sec.gov/edgar

www.sec.gov/edgar

. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements, except as required by applicable securities laws.

本新闻稿中包含的任何前瞻性陈述均截至本新闻稿发布之日作出，并基于管理层在该等前瞻性信息作出之日的信念、估计、预期和观点。除非适用证券法律另有要求，公司不承担更新前瞻性陈述的任何义务。

Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement..

投资者不应过度依赖前瞻性陈述。本新闻稿中包含的前瞻性陈述明确受此警示性声明的限定。

SOURCE IM Cannabis Corp.

来源：IM Cannabis Corp.